MINI FUTURE SHORT - NOVO-NORDISK B | Real-time Bid/Ask 13:29:41 04/06/2024 BST | ||
| 0.75 CHF / 0.77 CHF | -2.56% |
|
| Current month | -1.27% | ||
| 1 month | -39.06% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 03/06/24 | 0.78 | -1.27% |
| 31/05/24 | 0.79 | -7.06% |
| 30/05/24 | 0.85 | -2.30% |
| 29/05/24 | 0.87 | +2.35% |
| 28/05/24 | 0.85 | +2.41% |
Delayed Quote Swiss Exchange
Last update June 03, 2024 at 04:20 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| VKEABP | |
| ISIN | CH1332890875 |
| Date issued | 07/03/2024 |
| Strike | 1,044 kr |
| Maturity | Unlimited |
| Parity | 20 : 1 |
| Emission price | - CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 1.28 CHF |
|---|---|
| Lowest since issue | 0.71 CHF |
| Spread | 0.01 CHF |
| Spread % | 1.32% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
923.9
DKK
Average target price
917.3
DKK
Spread / Average Target
-0.71%
- Stock Market
- Certificates
- VKEABP Certificat